These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36173889)

  • 21. HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy.
    Álvarez B; Navarrete-Muñoz MA; Briz V; Olmedillas-López S; Nistal S; Cabello A; Prieto L; Górgolas M; García-Arranz M; Benito JM; Rallón N
    Sci Rep; 2022 Mar; 12(1):5095. PubMed ID: 35332180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients].
    Liao BL; Li LH; Zhong HL; Li H; Li YH; Chen SZ; Wen CY; Hu FY; Lan Y; Cai WP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Aug; 29(8):776-780. PubMed ID: 34517460
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals.
    Rossotti R; Merli M; Baiguera C; Bana NB; Rezzonico LF; D'Amico F; Raimondi A; Moioli MC; Chianura LG; Puoti M
    J Viral Hepat; 2023 Jun; 30(6):530-539. PubMed ID: 36773329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients.
    Macías J; Téllez F; Rivero-Juárez A; Palacios R; Morano LE; Merino D; Collado A; García-Fraile L; Omar M; Pineda JA;
    J Viral Hepat; 2019 Jan; 26(1):48-54. PubMed ID: 30199593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects.
    Zuccalà P; Latronico T; Marocco R; Savinelli S; Vita S; Mengoni F; Tieghi T; Borgo C; Kertusha B; Carraro A; D'Ettorre G; Vullo V; Mastroianni CM; Liuzzi GM; Lichtner M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study.
    Nikolaichuk M; Mocroft A; Wandeler G; Szlavik J; Gottfredsson M; Reikvam DH; Svedhem V; Elinav H; Laguno M; Mansinho K; Devitt E; Chkhartishvili N; Behrens G; Bogner J; Viard JP; Winston A; Benfield T; Leen C; Fursa O; Rockstroh J; Peters L;
    HIV Med; 2023 Feb; 24(2):224-230. PubMed ID: 35934954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
    Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
    Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
    Gayam V; Hossain MR; Khalid M; Chakaraborty S; Mukhtar O; Dahal S; Mandal AK; Gill A; Garlapati P; Ramakrishnaiah S; Mowyad K; Sherigar J; Mansour M; Mohanty S
    Gut Liver; 2018 Nov; 12(6):694-703. PubMed ID: 29938459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Well tolerability and highly effective treatment response for hepatitis C virus-human immunodeficiency virus-coinfected patients treated by all-oral direct-acting antivirals.
    Su PS; Su CW; Wu SH; Wei TH; Chu CJ; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2021 May; 84(5):465-471. PubMed ID: 33871393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients.
    Martín-Carbonero L; Domínguez-Domínguez L; Bailón L; Torres R; Rubio R; Ron R; Moreno F; Rico M; Jimenez-Nacher I; González-García J; Pulido F; Montes ML
    Enferm Infecc Microbiol Clin (Engl Ed); 2019; 37(6):367-372. PubMed ID: 30477904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
    Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
    Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study.
    Tsai CY; Chen GJ; Tsai CS; Liou BH; Yang CJ; Tsai HC; Lin CY; Huang SH; Lin KY; Wang NC; Chen TC; Lee CH; Hung CC;
    J Microbiol Immunol Infect; 2023 Aug; 56(4):718-728. PubMed ID: 37045634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection.
    Montes ML; Olveira A; Ahumada A; Aldámiz T; García-Samaniego J; Clemente A; Berenguer J; González-García J; Martín-Carbonero L;
    AIDS; 2017 Jun; 31(9):1253-1260. PubMed ID: 28358742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study.
    Alessio L; Onorato L; Sangiovanni V; Borrelli F; Manzillo E; Esposito V; Simeone F; Martini S; Capoluongo N; Leone S; Di Filippo G; D'Abbraccio M; Aprea L; Megna AS; Milano E; Rizzo V; Saracino A; Coppola N
    Antivir Ther; 2020; 25(4):193-201. PubMed ID: 32314978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
    Lacombe K; Fontaine H; Dhiver C; Metivier S; Rosenthal E; Antonini T; Valantin MA; Miailhes P; Harent S; Batisse D; Pageaux GP; Chas J; Aumaitre H; Dominguez S; Allegre T; Lafeuillade A; Billaud E; De Truchis P; Perre P; Leroy V; De Ledinghen V; Sogni P; Dabis F; Zhao Y; Filipovics A; Fedchuk L; Akremi R; Bennai Y; Salmon Ceron D
    J Acquir Immune Defic Syndr; 2017 May; 75(1):97-107. PubMed ID: 28272163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.